Aarti Pharmalabs · NSE: AARTIPHARM · BSE: 543748
Q1 FY25 results · Apr–Jun 2024
Aarti Pharmalabs reported revenue from operations of ₹555.49 crore (up 21.2% from Q1 FY24) and net profit of ₹55.45 crore (up 17.8% from Q1 FY24) for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 555.49 | 458.36 | +21.2% | 505.77 | +9.8% |
| Other income | 2.22 | 0.48 | +361.7% | 2.03 | +8.9% |
| Total income | 557.71 | 458.84 | +21.5% | 507.80 | +9.8% |
| Profit before tax | 73.68 | 63.98 | +15.2% | 95.75 | −23.1% |
| Net profit for the period | 55.45 | 47.09 | +17.8% | 65.25 | −15.0% |
| EPS, basic (₹) | 6.12 | 5.20 | +17.7% | 7.20 | −15.0% |
| Net margin (%) | 10.0 | 10.3 | 12.9 |
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 393.49 | 358.14 | +9.9% | 414.82 | −5.1% |
| Other income | 2.11 | 4.86 | −56.5% | 5.69 | −62.9% |
| Total income | 395.60 | 363.00 | +9.0% | 420.50 | −5.9% |
| Profit before tax | 63.23 | 62.13 | +1.8% | 91.28 | −30.7% |
| Net profit for the period | 47.14 | 47.63 | −1.0% | 63.02 | −25.2% |
| EPS, basic (₹) | 5.20 | 5.26 | −1.1% | 6.95 | −25.2% |
| Net margin (%) | 12.0 | 13.3 | 15.2 |
Consolidated
- Filed with BSE
- 06 Aug 2024, 10:46 IST
- Board meeting
- 05 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Aug 2024, 10:46 IST
- Board meeting
- 05 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Audited
- Source
- XBRL filing on BSE